These findings later confirmed that the acquisition of IDH1 mutants or high amounts of D-2-HG is sufficient to induce the hypermethylation phenotype identified among patients with IDH-mutated gliomas [18]. The gene discussed is IDH1; the disease is central nervous system cancer.